Johnson & Johnson to Post Q4 2022 Earnings of $2.22 Per Share, SVB Leerink Forecasts (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJGet Rating) – Research analysts at SVB Leerink dropped their Q4 2022 earnings per share (EPS) estimates for Johnson & Johnson in a report issued on Friday, January 20th. SVB Leerink analyst D. Risinger now anticipates that the company will post earnings per share of $2.22 for the quarter, down from their previous forecast of $2.24. SVB Leerink currently has a “Outperform” rating and a $186.00 target price on the stock. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.04 per share. SVB Leerink also issued estimates for Johnson & Johnson’s Q1 2023 earnings at $2.47 EPS, Q2 2023 earnings at $2.49 EPS, Q3 2023 earnings at $2.59 EPS, Q4 2023 earnings at $2.34 EPS, FY2023 earnings at $9.88 EPS, FY2024 earnings at $10.36 EPS, FY2025 earnings at $10.77 EPS and FY2026 earnings at $11.34 EPS.

Several other analysts have also recently issued reports on JNJ. Atlantic Securities reduced their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 19th. Morgan Stanley reduced their price objective on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Raymond James reduced their price objective on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Citigroup increased their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Finally, Barclays initiated coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Trading Down 0.5 %

JNJ opened at $168.74 on Monday. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The business has a fifty day simple moving average of $176.14 and a 200-day simple moving average of $171.20. The firm has a market cap of $441.17 billion, a P/E ratio of 23.50, a P/E/G ratio of 3.19 and a beta of 0.56. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37.

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares in the last quarter. State Street Corp boosted its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Johnson & Johnson by 3.3% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock valued at $4,154,022,000 after purchasing an additional 805,831 shares in the last quarter. Legal & General Group Plc boosted its holdings in Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares in the last quarter. Finally, FMR LLC boosted its stake in shares of Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Ashley Mcevoy sold 73,323 shares of the firm’s stock in a transaction dated Wednesday, November 30th. The stock was sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 233,611 shares of company stock worth $40,960,735. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.